{"id":"NCT00191646","sponsor":"Eli Lilly and Company","briefTitle":"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","officialTitle":"Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-10","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2005-09-19","resultsPosted":"2010-09-09","lastUpdate":"2011-03-04"},"enrollment":919,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Genital Neoplasms, Female","Fallopian Tube Neoplasms","Ovarian Neoplasms","Pelvic Neoplasms","Peritoneal Neoplasms"],"interventions":[{"type":"DRUG","name":"Gemcitabine","otherNames":["LY188011","Gemzar"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Gemcitabine/Carboplatin","type":"EXPERIMENTAL"},{"label":"Paclitaxel/Carboplatin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Baseline to measured progressive disease or death up to 82 months","effectByArm":[{"arm":"Gemcitabine/Carboplatin","deltaMin":20,"sd":null},{"arm":"Paclitaxel/Carboplatin","deltaMin":22.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.199"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":55,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":412},"commonTop":["Hemoglobin","White blood cells","Anc/agc","Fatigue","Platelets"]}}